News headlines about Dynavax Technologies Corporation (NASDAQ:DVAX) have been trending somewhat positive on Sunday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dynavax Technologies Corporation earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.6191107132033 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s rankings:
- Dynavax Technologies Corporation (DVAX) Earns “Buy” Rating from Cowen and Company (americanbankingnews.com)
- Dynavax Technologies Corporation (DVAX) Announces Earnings Results, Beats Estimates By $0.15 EPS (americanbankingnews.com)
- Facts About In Play Stocks: Dynavax Technologies Corporation (NASDAQ: DVAX) – Alpha Beta Stock (alphabetastock.com)
- Dynavax Reports Third Quarter 2017 Financial Results (finance.yahoo.com)
- Dynavax Technologies reports 3Q loss (finance.yahoo.com)
Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) opened at $21.60 on Friday.
Dynavax Technologies Corporation (NASDAQ:DVAX) last released its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.53) by $0.15. The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.28 million. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The company’s quarterly revenue was down 68.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.90) earnings per share. analysts expect that Dynavax Technologies Corporation will post -1.74 earnings per share for the current year.
DVAX has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Monday, July 10th. Cantor Fitzgerald initiated coverage on shares of Dynavax Technologies Corporation in a report on Friday, September 15th. They set an “overweight” rating and a $24.00 target price on the stock. Royal Bank Of Canada reissued a “buy” rating and set a $26.00 price target on shares of Dynavax Technologies Corporation in a research report on Friday, September 1st. Cowen and Company reissued an “outperform” rating and set a $45.00 price target on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. Finally, William Blair reissued an “outperform” rating on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $25.00.
About Dynavax Technologies Corporation
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
What are top analysts saying about Dynavax Technologies Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dynavax Technologies Corporation and related companies.